<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841226</url>
  </required_header>
  <id_info>
    <org_study_id>STC-001/E</org_study_id>
    <nct_id>NCT04841226</nct_id>
  </id_info>
  <brief_title>Randomized Study of Silq Urinary Catheter</brief_title>
  <official_title>Prospective, Multi-Center, Randomized Study to Assess the Ability of the Silq Cleartract™ Urinary Catheter to Reduce Biofilm Formation When Compared to Two Types of Commercially Available Foley Catheters (Silver-Coated Latex and Silicone-coated Latex)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silq Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silq Technologies Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the ability of the Silq Cleartract™ 100% Silicone 2-Way Foley Catheter to reduce&#xD;
      biofilm formation in subjects that require a long-term indwelling Foley catheter when&#xD;
      compared to other commercially available urinary catheters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, multi-center, post-market study in subjects that require a&#xD;
      long-term indwelling Foley catheter.&#xD;
&#xD;
      A randomly assigned catheter will be inserted using standard techniques. Non-surgical&#xD;
      subjects will rate the level of pain associated with the insertion procedure using the visual&#xD;
      analog scale (VAS). A urine sample will be collected immediately after catheter insertion, in&#xD;
      order to generate a baseline urinalysis and urine culture.&#xD;
&#xD;
      Follow-up visits will be performed on Day 28, or upon catheter removal, whichever occurs&#xD;
      first. The catheter will be removed on Day 28 or earlier if clinically indicated. The removed&#xD;
      catheter will be processed and sent to the core laboratory for analysis. Urine will be&#xD;
      collected immediately prior to catheter removal in order to conduct urinalysis and urine&#xD;
      culture. Subject will rate level of pain associated with the removal procedure using the VAS.&#xD;
      The subject will also fill out a questionnaire about their experience with the&#xD;
      catheterization immediately after catheter removal. Subjects will then be exited from the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biofilm formation</measure>
    <time_frame>5 to 7 days</time_frame>
    <description>A core lab will use the BacTiter-Glo Microbial Cell Viability Assay, a well characterized method for quantifying active biomass and biofilm, to determine biofilm formation on explanted catheter samples.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Biofilm Formation</condition>
  <condition>UTI</condition>
  <arm_group>
    <arm_group_label>Silq Cleartract™ 100% Silicone 2-Way Foley Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Up to 82 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Silver-coated Latex 2-Way Foley Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Up to 82 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Silicone-coated Latex 2-Way Foley catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Up to 82 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Long-term indwelling Foley catheter</intervention_name>
    <description>Foley Catheter inserted for up to 28-days</description>
    <arm_group_label>Silicone-coated Latex 2-Way Foley catheter</arm_group_label>
    <arm_group_label>Silq Cleartract™ 100% Silicone 2-Way Foley Catheter</arm_group_label>
    <arm_group_label>Silver-coated Latex 2-Way Foley Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men age ≥ 18 years old;&#xD;
&#xD;
          2. Requiring indwelling 16Fr Foley catheter for at least 7 days;&#xD;
&#xD;
          3. Able and willing to comply with study procedure; and,&#xD;
&#xD;
          4. Able and willing to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy or sensitivity to any catheter materials used in this study;&#xD;
&#xD;
          2. Known urethral stricture which, in the opinion of the investigator, could influence&#xD;
             the subject's evaluation of the catheter;&#xD;
&#xD;
          3. Planned Prophylactic use of antibiotics for CAUTI beyond day 1 of the study (catheter&#xD;
             implantation);&#xD;
&#xD;
          4. Symptomatic UTI being treated with antibiotics (as determined by the study PI,&#xD;
             including at least one of the following: fever, chills, headache, burning sensation,&#xD;
             burning of urethra or genital area, blood in urine, foul smelling urine and ≥ 10,000&#xD;
             cfu/mL);&#xD;
&#xD;
          5. Any other infection being treated with antibiotics at the time of catheter&#xD;
             implantation;&#xD;
&#xD;
          6. Currently enrolled in another interventional clinical trial; and&#xD;
&#xD;
          7. Any other condition that, in the opinion of the investigator, precludes study&#xD;
             participation or poses a significant hazard in case of study participation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brian McVerry, PhD</last_name>
    <phone>949-735-2614</phone>
    <email>brianm@silq.tech</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Catheter</keyword>
  <keyword>Foley</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

